EA
GYRE icon

Edge Advisors’s Gyre Therapeutics GYRE Stock Holding History

Edge Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$0 Hold
6
– – ﹤0.01% 860
2018
Q1 		$1K Hold
6
– – ﹤0.01% 838
2017
Q4 		$0 Hold
6
– – ﹤0.01% 934
2017
Q3 		$0 Hold
6
– – ﹤0.01% 922
2017
Q2 		$0 Hold
6
– – ﹤0.01% 959
2017
Q1 		$0 Hold
6
– – ﹤0.01% 956
2016
Q4 		$0 Buy
+6
New +$540 ﹤0.01% 851

Other funds holding GYRE

ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Edge Advisors's GYRE Position: Q2 2018 in Review

Edge Advisors held its Gyre Therapeutics (GYRE) position steady in Q2 2018 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Edge Advisors first reported a position in GYRE in Q4 2016 and has held it in 7 quarters since. The position peaked at $1K in Q1 2018. 75 funds tracked by Wall St. Rank hold GYRE as of Q2 2018.

  • Edge Advisors held 6 shares of Gyre Therapeutics worth $0 as of Q2 2018.
  • Edge Advisors left its Gyre Therapeutics share count unchanged in Q2 2018.
  • Gyre Therapeutics made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #860 holding.
  • Edge Advisors first reported a position in Gyre Therapeutics in Q4 2016 and has held it in 7 quarters since.
  • Edge Advisors's Gyre Therapeutics position peaked at $1K in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.